Secretagogue, reference only
CJC-1295 with DAC
GHRH(1-29) analog covalently tethered to albumin via a maleimidopropionyl linker; ~7-day human half-life.
CJC-1295 with DAC is not in our range right now. This page documents it from the literature for research reference only, not for human use. Compounds available to order are listed below.
Specification
- Molecular weight
- 3,647.25 Da
- Half-life
- 7 d
- Research area
- Secretagogue
Also called CJC-1295 DAC, DAC:GRF, Drug Affinity Complex GRF
5.8–8.1 days (~140–195 h) in humans SC; mean ~7 days. DAC = maleimidopropionic acid linker forming a covalent thioether bond to Cys34 of serum albumin. Teichman et al., J Clin Endocrinol Metab 2006.
About the research
CJC-1295 with DAC was developed by ConjuChem as a long-acting GHRH analog using their Drug Affinity Complex platform — a maleimide moiety that forms a stable covalent bond with serum albumin Cys34 in vivo. The resulting bioconjugate produces multi-day elevation of GH and IGF-1, in contrast to the pulsatile signaling of native GHRH, and is studied as both a research tool and historical clinical candidate.
Mechanism, reported research areas, literature dose ranges and co-factor studies are on the research page, with sources. Nothing there is a claim about this product.
Read the CJC-1295 with DAC research overview- Sustained IGF-1 elevation research
- Combination protocols with ghrelin-mimetics (e.g., ipamorelin)
- Body-composition and recovery research models
- Aged-rodent somatotroph axis restoration studies
- Reported research areas, from the literature. Not product claims.
In stock now
All products
Wolverine Blend€119.90Repair
